Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:広義の開放隅角緑内障治療におけるプロスタグランジン製剤とβ遮断薬点眼液からトラボプロスト・チモロールマレイン酸塩配合点眼液(デュオトラバ®)への前向き切替え試験結果の報告。対象と方法:40例78眼を対象とした。変更前,2,4,6か月後の眼圧とアンケート調査を行った。結果:眼圧は変更前が15.2±3.7mmHgに対し,変更後2か月で14.3±3.4mmHg,4か月で15.0±3.4mmHg,6か月で14.1±3.4mmHgで,変更後2か月,6か月で有意に下降した。アンケート結果は23例から回答が得られ,点眼が楽になった患者は18例,点眼し忘れが減った患者は12例であった。結論:デュオトラバ®はアドヒアランスの改善が見込め,切替えによってさらに眼圧下降する可能性がある。
Abstract. Purpose:To report the outcome of switching from prostaglandins and beta-blockers to a fixed combination of travoprost and timolol for glaucoma. Cases and Method:This prospective study was made in 11 institutions on 78 eyes of 40 patients with open-angle glaucoma who were under treatment with topical prostaglandins and beta-blockers. The treatment was switched to a fixed combination of travoprost and timolol. Intraocular pressure(IOP)was measured before and after treatment. Patients were asked by questionnaire after switching. Results:IOP averaged 15.2±3.7 mmHg before switching. It decreased significantly to 14.3±3.4 mmHg two months after switching and to 14.1±3.4 mmHg six months after switching. Response to questionnaire was obtained from 23 patients. Ease of self-medication was reported by 18 patients. Twelve patients forgot to apply the medication less frequently. Conclusion:The fixed combination of travoprost and timolol in this study promises to further reduce IOP and to improve the adherence in glaucoma patients.
Copyright © 2012, Igaku-Shoin Ltd. All rights reserved.